In a claim earlier this month, Balakrishna had said that ayurvedic medicine developed by Patanjali was able to cure at least 1,000 coronavirus patients within 5-14 days.
Haridwar| Consumer goods and herbal medicine company Patanjali, started by Baba Ramdev to promote domestic-made products, will today launch its Ayurvedic medicine, Coronil, to treat coronavirus patients in Haridwar.
“Proud launch of first and foremost evidence-based ayurvedic medicine for #corona contagion, #SWASARI_VATI, #CORONIL, is scheduled for tomorrow at 12 noon from #Patanjali Yogpeeth Haridwar,” the Chief Executive Officer, Balakrishna, tweeted on Monday.
https://twitter.com/Ach_Balkrishna/status/1275059403750703116?s=20
In a claim earlier this month, Balakrishna had said that ayurvedic medicine developed by Patanjali was able to cure at least 1,000 coronavirus patients within 5-14 days.
Balakrishna, explaining the entire process, had said that Patanjali had appointed a team of scientists the moment the fatal virus started spreading outside China. He said, “Firstly, the simulation was done and compounds were identified which can fight the virus. Then we conducted a clinical case study on hundreds of positive patients and we have got 100 per cent favourable results,” reported Business Today.
According to news agency ANI, Balakrishna also said, “After taking our medicine, COVID patients recovered in 5-14 days and then tested negative. So, we can say the cure for COVID is possible through Ayurveda. We are performing controlled clinical trials only. In the next 4-5 days, evidence and data will be released by us.”
Advising people to stay safe during the pandemic, Balakrishna said people should practice yoga, and keep themselves healthy through proper diet to boost the immune system.
On the other side, while Glenmark Pharmaceuticals has launched favipiravir under the brand name FabiFlu for treatment of mild to moderate cases of Covid-19, Cipla, and Hetero Labs have received approvals from the Drug Controller General of India to launch generic versions of Remdesivir under the brand names Cipremi and Covifor respectively.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
